EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacogenomic panel testing for personalized supportive oncology

D Grace Nguyen, Sarah A Morris, Danielle M Boselli, Alicia Hamilton, Mathew Smith, Nury Steuerwald, James T Symanowski, Kunal C Kadakia, Declan Walsh, Jai N Patel

Supportive Care in Cancer · 2026-12 · 34 (12)

DOI: 10.1007/s00520-026-11489-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 17.11.2026. Verfasst von D Grace Nguyen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC, 28204, USA. Hauptthemen laut MEDLINE: Neoplasms, Pharmacogenomic Testing, Precision Medicine. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, Wake Forest University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Drug response for cancer symptom management is variable. The purpose of this trial is to study the impact of multigene pharmacogenomic (PGx) testing on drug prescribing in supportive oncology.

Methods

This is a single-arm prospective trial of adults with cancer referred to the supportive oncology clinic with Edmonton Symptom Assessment System pain ≥ 4, depression ≥ 3, or requiring antidepressant modification. Patients were genotyped for variants in CYP3A4 , CYP3A5 , CYP2D6 , CYP2C9 , CYP2C19 , CYP2B6 , COMT , OPRM1 , SLC6A4 , and HTR2A , and assessed every 4 weeks up to a maximum of 16 weeks. Primary endpoint was the proportion of patients with ≥ 1 PGx-guided intervention. Secondary endpoints included the type/frequency of drug-gene interactions (DGIs) at baseline and final visits, and the type/frequency of interruptive PGx alerts in the electronic health record (EHR).

Results

70 patients were genotyped (54% female, 67% White, 33% Black, median age 59). Gynecologic (21%), breast (14%), and hematologic (14%) cancers were most common, and 64% had stage III or IV disease. 50% and 59% carried a CYP2D6 or CYP2C19 non-normal metabolizer phenotype, respectively. Of 66 evaluable patients, 9 (14%, 95% CI 7–24%) had a PGx-guided intervention, mostly for opioids and antidepressants. At baseline and final visits, 25 (n = 23; 35%) and 22 (n = 21; 32%) DGIs, respectively, were present. There were 26 interruptive alerts triggered for 10 (18%) of 56 patients evaluable for PGx alerts, mostly for CYP2C19-proton pump inhibitors (PPIs) and CYP2C19/CYP2B6-antidepressants.

Conclusion

DGIs, mostly for opioids, antidepressants, and PPIs, were common and PGx-guided interventions occurred in a minority of patients. Interruptive alerts were frequent and prompted PGx-guided interventions in most patients with actionable interactions, highlighting the opportunity to optimize EHR-based clinical decision support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPharmacogenomic TestingPrecision MedicineHumansFemaleProspective StudiesMiddle AgedMaleAgedAdultDepressionAntidepressive AgentsGenotypePharmacogeneticsCancer Pain

Stichwörter der Autor:innen

PharmacogeneticsPharmacogenomicsPrecision medicineSupportive oncologySymptom management

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Division of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC, 28204, USA.
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
  • Department of Biostatistics and Data Sciences, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.
  • Biostatistics Shared Resource, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC, USA.
  • Molecular Biology and Genomics Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.
  • Cancer Genomics Shared Resource, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC, USA.

Förderung

  • NCI NIH HHS
  • American Cancer Society
  • Wake Forest University

Zitieren

APA

Nguyen, D. G., Morris, S. A., Boselli, D. M., Hamilton, A., Smith, M., Steuerwald, N., Symanowski, J. T., Kadakia, K. C., Walsh, D., & Patel, J. N. (2026). Pharmacogenomic panel testing for personalized supportive oncology. Supportive Care in Cancer, 34(12). https://doi.org/10.1007/s00520-026-11489-x

Vancouver

Nguyen DG, Morris SA, Boselli DM, Hamilton A, Smith M, Steuerwald N, et al. Pharmacogenomic panel testing for personalized supportive oncology. Supportive Care in Cancer. 2026;34(12). doi:10.1007/s00520-026-11489-x

BibTeX
@article{Nguyen2026,
  author = {Nguyen, D Grace and Morris, Sarah A and Boselli, Danielle M and Hamilton, Alicia and Smith, Mathew and Steuerwald, Nury and Symanowski, James T and Kadakia, Kunal C and Walsh, Declan and Patel, Jai N},
  title = {Pharmacogenomic panel testing for personalized supportive oncology},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {12},
  doi = {10.1007/s00520-026-11489-x}
}
Kostenlos starten →